ENB Therapeutics, Inc. — Form D/A
ENB Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2020-02-13. The offering totals $9.1M, of which $8.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-02-13
- Form: D/A
- Accession: 0001104659-20-019980
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $9.1M
- Amount sold: $8.1M
- Remaining: $1.0M
- Investors: 17
- Date of first sale: 2018-09-07
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-321893
Issuer
- Name: ENB Therapeutics, Inc.
- CIK: 0001753420
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: C/O LAUNCHLABS, NEW YORK, NY, 10016
- Phone: 212 792-2317
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Sumayah Jamal | Director | New York, NY |
| Sumayah Jamal | Executive Officer | New York, NY |
| Barbara Schilberg | Director | New York, NY |
| Stuart Hwang | Director | New York, NY |
| Walter Olesiak | Director | New York, NY |
| Albert Sokol | Executive Officer | New York, NY |
| Fumitaka Mori | Director | NEW YORK, NY |
Other filings by this issuer (3)
More